Denali Therapeutics Inc. DNLI
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Growth
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
Each USD of equity lost 46 cents this year.
The 10-year record
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.3 | 0.1 | 0.0 | 0.3 | 0.0 | 0.1 | 0.0 | 0.0 |
| Operating income $B | −0.6 | −0.5 | −0.2 | −0.3 | −0.3 | 0.1 | −0.2 | −0.0 | −0.1 | −0.1 |
| EBITDA $B | −0.5 | −0.5 | −0.2 | −0.3 | −0.3 | 0.1 | −0.2 | −0.0 | −0.1 | −0.1 |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 | −0.0 | 0.0 | 0.0 | ◌ |
| Net income $B | −0.5 | −0.4 | −0.1 | −0.3 | −0.3 | 0.1 | −0.2 | −0.0 | −0.1 | −0.1 |
| Free cash flow $B | −0.4 | −0.4 | −0.4 | −0.3 | −0.2 | 0.4 | −0.2 | 0.0 | −0.1 | −0.1 |
| EPS, diluted $ | −2.97 | −2.57 | −1.06 | −2.60 | −2.39 | 0.63 | −2.07 | −0.39 | −5.89 | −13.49 |
| Dividend / sh $ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — | — | — | — | — | — | — | — |
| ROE % | −45.7 | −37.4 | −14.0 | −32.5 | −27.5 | 9.2 | −42.0 | −7.2 | — | — |
| Shares out B | 0.16 | 0.14 | 0.14 | 0.14 | 0.12 | 0.12 | 0.10 | 0.09 | 0.09 | ◌ |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Company facts, as filed
Reconciled in 10 of the 10 fiscal years we could check. 20 checks were skipped: the balance sheet is not tagged before 2017. Nine checks were skipped: EPS is not tagged before 2016.